Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma

Castration-resistant Prostate Cancer Clinical Trial

— Apa-CARDIO1  

Official title:

Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04567875
• Other study ID #: APA-CARDIO_PAG_01
• Status: Recruiting
• Start date: July 16, 2020
• Est. completion date: September 2022

Study information

• Verified date: September 2020
• Source: Ospedale Andrea Tortora di Pagani
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani. Data will be collected on the patient's clinical history and the treatments carried out until the start of therapy with Apalutamide. At that time the study will be described to the patient and informed consent will be given.

In case of a favorable opinion from the patient, the CRF will be filled in. Patients with CRPC M0 treated with Apalutamide, belonging to the Oncology Unit of the Pagani Hospital "Andrea Tortora" and of the other Oncology Units of the ASL of Salerno (Hospital of Vallo della Lucania) will be studied with the possibility of enrollment also from other Centers outside the Salerno ASL.

Description:

The CRPC M0 patient will be identified by PET PSMA, or CT scan and Bone Scanning at the clinician's discretion based on the physical examination performed at the patient's first access. The reassessment of the disease status is to be repeated by PET-PSMA, CT scan or bone scan (in relation to the examination carried out at baseline) in a period of time ranging from 6 to 12 months after the first access, based on the assessment of the health status of the patient and tolerability to treatment after careful evaluation by the clinician. The blood chemistry routine including CBC with white blood cell formula will be repeated every 30 days. The patient will be provided with a blood pressure monitoring diary every 30 days. The measurement of cardiac markers will be performed every 60 days. The evaluation of the cardiological function will be carried out by means of ECG, echocardiography with determination of the LVEF, 24-hour Holter blood pressure every 6 months. Bone mineral density assessment will be monitored by MOC-DEXA every 6 months. Possible drug interactions with Apalutamide will be identified.

Primary objective:

-Evaluation of arterial hypertension, by periodic measurement of blood pressure every week (1-3 times), creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months, with stratification of patients under treatment according to the degree of AI found.

Secondary objectives:

• Evaluation of cardiological toxicity, through the execution of ECG, periodic echocardiography for the evaluation of the ejection fraction of the left ventricle, cardiac markers (troponin, CK-MB, pro-BNP)

• Assessment of the biochemical response, such as a 50% reduction in total PSA compared to baseline in patients receiving apalutamide;

• Evaluation of the change in blood chemistry parameters in the patient being treated with Apalutamide;

• Relationship between changes in blood chemistry parameters and time to the onset of metastases, assessed by PET PSMA or bone scan or CT scan;

• Relationship between changes in blood chemistry parameters and overall survival;

• Relationship between changes in blood chemistry parameters and occurrence of serious adverse events;

• Association between basophil counts and appearance of skin rash;

• Evaluation of drug interactions with Apalutamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: September 2022
• Est. primary completion date: March 2022
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• CRPC patients without evidence of distant metastasis are eligible

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Cardiotoxicity
• Castration-resistant Prostate Cancer
• Hypertension
• Prostatic Neoplasms

Intervention

Other:
• No Intervention on patients
No Intervention on patients

Locations

Country	Name	City	State
Italy	Oncology Unit, Hospital Andrea Tortora	Pagani	Salerno
Italy	Oncology Unit, Ospedale Andrea Tortora	Pagani	Salerno

Sponsors (1)

Lead Sponsor	Collaborator
Ospedale Andrea Tortora di Pagani

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months	Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months	Almost 1 year
Secondary	Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide	Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide	Almost 1 year
Secondary	Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan	Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan	Almost 1 year
Secondary	Relationship between changes in blood chemistry parameters and overall survival	Relationship between changes in blood chemistry parameters and overall survival	Almost 1 year
Secondary	Relationship between changes in blood chemistry parameters and occurrence of serious adverse events	Relationship between changes in blood chemistry parameters and occurrence of serious adverse events	Almost 1 year
Secondary	Association between basophil count and appearance of skin rash	Association between basophil count and appearance of skin rash	Almost 1 year
Secondary	Evaluation of drug interactions with Apalutamide	Evaluation of drug interactions with Apalutamide	Almost 1 year